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Abstract
Background—Clinic-based blood pressure (CBP) has been the default approach for diagnosing
hypertension, but patients may be misclassified due to masked hypertension (false negative) or
“white coat” hypertension (false positive). The incorporation of other diagnostic modalities, such
as home blood pressure monitoring (HBPM) and ambulatory blood pressure monitoring (ABPM),
holds promise to improve diagnostic accuracy and subsequent treatment decisions.
Method—We reviewed the literature on the costs and cost-effectiveness of adding HBPM and
ABPM into routine blood pressure screening in adults. We excluded letters, editorials, and studies
of pregnant and/or pre-eclamptic patients, children, and patients with specific conditions (e.g.
diabetes).
Results—We identified 14 original, English language studies that included cost outcomes and
compared two or more modalities. ABPM was found to be cost-saving for diagnostic confirmation
following an elevated CBP in 6 studies. Three of 4 studies found that adding HBPM to an elevated
CBP was also cost-effective.
Conclusion—Existing evidence supports the cost-effectiveness of incorporating HBPM or
ABPM following an initial CBP-based diagnosis of hypertension. Future research should focus on
their implementation in clinical practice, long-term economic values, and potential roles in
identifying masked hypertension.
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According to the Centers for Disease Control and Prevention, approximately one out of
every three United States (US) adults is hypertensive [1]. Uncontrolled hypertension is
associated with higher cardiovascular and overall mortality [2] and is present in nearly 75%
of US adults diagnosed with coronary artery disease, congestive heart failure,
cerebrovascular disease, or diabetes mellitus [3]. In 2010, hypertension was estimated to
cost the US $76.6 billion in health care services, medications, and missed work days [4].
The U.S. Preventive Services Task Force endorses a Grade A recommendation for screening
adults age 18 and older for hypertension [5]. In a previous review, researchers found several
studies that demonstrated the efficacy and effectiveness of detecting elevated blood pressure
and introducing anti-hypertensive treatment as part of routine health visits for reducing
future mortality and morbidity; however, evidence on the cost-effectiveness of various blood
pressure monitoring techniques was not available [6].
Traditionally, the diagnosis of hypertension or “pre-hypertension” is made by taking blood
pressure measurements in the clinic. According to the Joint National Committee VII
(JNC-7) report [7], the diagnosis of hypertension in adults is made when the average of two
or more diastolic blood pressure measurements on at least 2 visits is ≥90 mmHg or when the
average of two or more systolic blood pressure measurements on at least 2 visits is 140
mmHg. In addition, ‘prehypertension’ is defined as having an average diastolic blood
pressure of 80–89 mmHg or average systolic blood pressure of 120–139 mmHg.
However, there are two major caveats to the diagnosis and treatment of hypertension based
solely upon clinic blood pressure: namely, the possibilities of false positive and false
negative diagnoses (Figure 1). “White coat” hypertension is defined as clinic hypertension
(mean SBP is ≥140 mmHg or mean DBP ≥90 mmHg) without ambulatory hypertension
(defined as mean awake blood pressure ≥ 135/85 mmHg) [8]. In the absence of ABPM,
these patients are likely to be treated despite having normal “true” or “usual” blood pressure,
and thus are exposed to unnecessary risks for adverse effects and treatment costs.
Conversely, “masked hypertension” is present when the clinic blood pressure is below
140/90 mmHg but the average blood pressure in one’s normal living environment meets the
criterion for hypertension [9] – i.e., where CBP yields a false negative diagnosis. These
patients are left untreated in spite of their elevated blood pressure levels. In general, patients
with white coat hypertension are shown to have better prognosis than those with true
hypertension, and patients with masked hypertension appear to experience worse outcomes
than those truly normotensive [10]. These observations underlie the limitations of relying on
CBP alone for diagnosing treatment-eligible patients and the opportunities for out-of-clinic
blood pressure measurement modalities to optimize patient outcomes.
Support for the addition of ambulatory blood pressure monitoring (ABPM) and/or home
blood pressure monitoring (HBPM) measures to the diagnostic algorithms as part of routine
care has been modest [5]. However, the UK National Health Services recently revised their
blood pressure screening guideline to support the routine use of ABPM to confirm a new
diagnosis of hypertension. The new guideline estimated a potential savings of £10 million
($16 million) over 4–5 years, mainly from the identification of white-coat hypertension and
subsequent reduction in treatment-associated costs [11]. Others advocate for using HBPM as
a cost-effective strategy to augment CBP-based usual care with fewer physician visits [12–
16], citing its greater accuracy as a measure of “usual blood pressure”, greater
reproducibility, greater prognostic value for cardiovascular outcomes, and low cost [16].
JNC-7 guidelines suggested a potential role of blood pressure self-measurement of
hypertensive patients [7], but did not endorse its routine use; international guidelines
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endorse a wider use of HBPM for monitoring treatment [17–19]. The limited uptake and
reimbursement for ABPM and HBPM may be due to a knowledge gap about its cost-
effectiveness compared to CBP. In this article, we provide an overview of the existing
literature on the comparative cost and cost-effectiveness of ABPM and CBP for
hypertension screening.
METHOD
Independent searches of PubMed, Medline, and the Tufts Cost Effectiveness Analysis
(CEA) Registry were carried out by authors AK and MN for studies published in the past 25
years. Citations and reference lists were also reviewed to identify additional studies. We
used the following search terms: adult, hypertension, blood pressure, screening, diagnosis;
cost-effectiveness, cost-benefit, cost analysis, cost utility, cost impact; clinic, ambulatory,
home; multiple combinations of search terms were used to maximize results from the
searches. We included original English-language studies that compared two or more
modalities of blood pressure measurement, for the purposes of primary prevention. Letters
and editorials were excluded. We also excluded studies that were restricted to
subpopulations of pregnant and/or pre-eclamptic patients; patients with specific
comorbidities (i.e., diabetes, coronary artery disease); and/or patients undergoing treatment
using a particular drug or device. All eligible articles were audited by AK and JN
independently, and disagreements were resolved by all authors.
We report the year of publication, country, study population, study design, time horizon, and
main findings. We also report the original cost figures as well as standardized 2011 US
dollars to allow comparisons across studies including various currencies and years of
analysis.
RESULTS
Fourteen studies were identified as meeting our eligibility criteria (Table 1). Nine of the 14
studies are clinical trials, while five are model-based decision analyses. The earliest study
was published in 1988[20]. Seven out of 14 of the studies were conducted in Europe; 4 were
conducted in the US; 2 were conducted in Japan; and one was conducted in Australia. Nine
studies compared ABPM to CBP alone[20–28], four studies compared HBPM to CBP [12–
15], and one study compared all three [11].
Comparing ABPM to CBP
In general, compared to CBP alone, most researchers found ABPM to be cost-saving. This
cost-saving was achieved mainly through increases in diagnostic accuracy resulting in a
reduction in overtreatment due to false-positive diagnoses of hypertension based on CBP
alone [11, 21–23, 25, 27, 28]. For example, in two separate studies, Krakoff et al found that
over a period of three years the cumulative costs of treatment for mild hypertension are
lower for those using ABPM compared to CBP only [20, 27]. These researchers also
estimated a 3–14% reduction in medical costs (which correlated with a 10–23% reduction in
treated patient-days) as long as annual treatment costs are no more than $300. Yarows et al
estimated that the cessation of unnecessary anti-hypertensives in patients with white-coat
hypertension could offset the cost of ABPM after one year when ABPM costs $188 or less
[29]. When ABPM was used as a secondary diagnostic modality, Pierdomenico et al found a
savings of $110,819 by using ABPM every two years over a six-year period, compared to
annual screening using CBP alone [22]. Rodriguez-Roca et al found that the cost of
achieving a well-controlled hypertension case is €940 ($1,169) with CBP and €238 ($296)
with ABPM, resulting in in €115 ($143 in 2011 US dollars) per additional well-controlled
case achieved [28]. In a secondary prevention study by Lorgelly et al, ABPM successfully
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identified patients with white coat hypertension, but at an annual cost of £3612 ($6641 in
2011 US dollars) [26]. Long-term savings were also found by a number of additional ABPM
studies [23, 25]. After measuring both consultation and medication costs, Aitken et al
demonstrated that the initial costs of ABPM were recouped after 1–2 years [23]. Similarly,
Ewald and Pekarsky constructed a model to evaluate the cost and effectiveness of ABPM
conducted every one, two, or three years [25]. Over a seven-year period, all three strategies
broke even after the third year, with subsequent savings ranging from $34 to $53 per year
per patient.
On the other hand, two research teams found no net savings of ABPM compared to CBP. In
a randomized control trial published in 1997 by Staessen et al., the researchers found that
despite more patients in the ABPM arm being considered a false positive and having their
anti-hypertensive treatment discontinued than in the CBP arm and more patients in the CBP
arm progressing to multi-drug treatment than in the ABPM arm, the savings at 1 year was
not sufficient to offset the cost of ABPM [24]. However, the range of follow-up for this
study was only 85–258 days, which might be an inadequate time period in which to observe
savings. Similarly, Lorgelly et al. [26] found that ABPM increased the cost of hypertension
control at a rate of £31 ($57 in 2011 US dollars) per patient over one year.
Comparing HBPM to CBP
There were two randomized controlled trials comparing HBPM to CBP. Staessen et al, 2004
[15] found that HBPM was associated with worse hypertension management despite
marginally lower costs. At one month, average medical costs per 100 patients were $4473
with HBPM versus $4921 without HBPM; however, mean blood pressure was also higher in
the HBPM group. General well-being and left ventricular mass did not appear to differ
between the two groups. Note, however, that the authors used a threshold for HBPM of
140/90 mmHg to define hypertension control, rather than the generally accepted 135/85
mmHg cut-off. In contrast, in their year-long clinical trial Soghikian et al found that the
mean costs for hypertension care were 29% less in patients managed via HBPM compared
to usual clinic-based care [14].
Three of the four modeled analyses comparing HBPM to CBP found HBPM to be cost-
effective [12–15]. Using data from the Ohasama study and a Markov model, Fukunaga et al
estimated the cost of incorporating HBPM into the diagnosis of hypertension in the Japanese
population [12]. They estimated that the incorporation of HBPM could reduce medical costs
by $US 1.56 million for every 1,000 patients over 5 years. When they varied the assumed
prevalence of white coat hypertension from 8.2 to 24.7% in the sensitivity analysis, the
resulting cost reduction ranged from $0.8 to 2.0 million. Using the same data but modeling a
decision tree analysis, Funahashi et al estimated that broad implementation of HBPM could
result in a saving of $9.3 billion US dollars in hypertension-related medical costs in
Japan[13]. These cost savings came mainly from identifying white coat hypertension.
Moreover, HBPM also contributes to better control and prognosis of true hypertensives,
saving approximately $28 million in annual medical costs from the prevention of
hypertension-related complications and $39 million annually from stroke prevention. It is
worth noting that, because stroke occurs at greater incidence in the Japanese population
relative to coronary heart disease (whereas coronary artery disease and MIs are much more
prevalent than stroke in the U.S. and Western European societies), their study placed a
greater emphasis on the role of hypertension control on stroke prevention.
Comparing ABPM, HBPM and CBP
Using a state-transition Markov model, Lovibond et al. [11] is the only study that compared
ABPM, HBPM and CBP. The study based the sensitivity and specificity of CBP (sensitivity
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85.6% (95% CI 81.0–89.2); specificity 45.9% (95% CI 33.0–59.3)), HBPM (sensitivity
85.7% (95% CI 78.0–91.2); specificity 62.4% (95% CI 48.0–75.0)), and ABPM (both 100%,
considered gold standard) on a published meta-analysis[30]. From the perspective of the
British National Health Services, the study found that ABPM was cost-saving in reducing
unnecessary treatment and future risks of coronary heart disease and stroke for men and
women of all ages.
DISCUSSION
Based on our review, existing studies suggest that supplementing CBP with HBPM or
ABPM is cost-effective for improving the diagnosis of hypertension and subsequent
treatment decisions. While differences in the study population and analytic methods exist,
this conclusion is consistent across the literature reviewed. These economic evaluations
suggested that adding HBPM or ABPM after detecting elevated BP in the clinic setting
could be worthwhile for identifying white coat hypertension and avoiding unnecessary
treatment.
Despite these consistent findings on the comparative value of HBPM and ABPM, the
translation of these findings into practice is modest and broad implementation of these
modalities into clinical practice have not occurred. This may be due to the marginal cost
savings found in some studies.
As the clinical benefit of BP measures hinges on the probabilities of false positive and false
negatives (Figure 1), identifying subpopulations most likely to be misclassified by CBP
alone will be important in maximizing cost-effectiveness. As noted by Krakoff [27], the use
of ABPM to diagnose hypertension may be most cost-effective when the prevalence of
white coat hypertension is high and when the annual incidence of new hypertension is low.
In four population-based European studies, researchers found that ambulatory pressure
shows much less increase with age than CBP [31–34]. We found few studies examining the
compliance issues associated with HBPM/ABPM. As the utility of these modalities depends
on patient cooperation, existing studies based on trial populations or modeling assumptions
are likely to represent an overestimate of the cost-effectiveness of these modalities.
Both ABPM and HBPM can add accuracy and value beyond simply correcting the CBP
measurement. For instance, ABPM can reveal nocturnal hypertension, a relatively new
marker of cardiac risk that has been shown to refine cardiovascular risk stratification above
and beyond that of conventional BP measurement, both in untreated subjects with white coat
hypertension and those with resistant hypertension [35, 36]. ABPM is also currently
regarded as the ‘gold standard’ for the prediction of risk; however, the role of ABPM in
diagnosing masked hypertension is uncertain, and it remains the most expensive of the 3
modalities [37]. The degree to which HBPM, a less expensive out-of-office option, can
adequately substitute for ABPM is unknown. However, there is increasing evidence that
HBPM is a good predictor of left ventricular hypertrophy and cardiovascular events,
including mortality. HBPM also has better prognostic accuracy than CBP for predicting the
future development of hypertension, and may be particularly useful for monitoring anti-
hypertensive treatment effects [29, 38, 39]. HBPM has the added bonus of eliminating the
white coat effect entirely, and can substantially increase patients’ awareness of their own
blood pressure, which may lead to better compliance with treatment [40]. However, HBPM
may not be suitable for all patients (e.g., obese patients with large arm sizes or the elderly)
and is subject to the same operator issues as CBP. While most studies show that HBPM
lowers costs, one study (but not others) also found that when used alone, it decreased BP
control [15].
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Based on our review, existing studies have characterized the clinical benefits of HBPM and
ABPM for identifying white coat hypertension (false positives); however, more research is
needed to assess how HBPM and ABPM may best be used to identify masked hypertension
(false negatives). A reasonable approach may be to prescribe ABPM or HBPM for patients
with CBP in the high-normal range (130–139/85–89 mmHg) or pre-hypertensive (120–
139/80–89 mmHg) range. One might also consider the presence/absence of other
cardiovascular risk factors in deciding who could benefit most from ABPM or HBPM
following a normal CBP. The value of identifying individuals with masked hypertension
parallels the well-established clinical benefit and cost-effectiveness of treating previously
undiagnosed hypertension. However, unlike observing cost savings from avoiding treatment
among white-coat hypertensives, the cost savings will come from downstream events
avoided and therefore the research will require a longer follow-up time. This need for a
long-term perspective highlights the value of model-based studies that enable us to weigh
immediate set-up costs with downstream treatment costs avoided, possibly several decades
later [11–13, 27].
It is worth noting that researchers and clinicians should not overlook ways to improve the
accuracy of CBP. CBP employs the traditional auscultatory technique with a trained
technician and a sphygmomanometer. Various types of equipment are still used, including
mercury (rarely); aneroid devices (require frequent calibration); and automatic devices with
electronic transducers, which are becoming more and more common [41] and can potentially
minimize the white coat effect of CBP at a reasonable cost [42]. Training of the operator,
positioning of the patient, and cuff size can all make a difference in measurement, and are
all factors that contribute to the poor correlation between CBP and other types of blood
pressure measurement, especially outside the research setting. Additionally, there needs to
be greater recognition of the fact that BP is a dynamic variable, of which CBP provides only
a snapshot. Even if CBP is the sole diagnostic assessment method, treatment decisions
should be based on multiple visits with multiple readings taken during each visit.
As the UK National Health Services begins to cover ABPM following an initial CBP
assessment as part of routine care [11], we anticipate increased discussion about the
potential utility of following similar diagnostic algorithms in U.S. clinical guidelines.
Additional population-based evidence from the UK will also fill key knowledge gaps on the
longer-term merits and unintended consequences of these practices. Furthermore, as the field
of cardiovascular prevention moves towards a global risk-based approach rather than single
risk factor approach, diagnostic accuracy of blood pressure may have implications beyond
hypertension treatment. For instance, the Adult Treatment Panel (ATP) 3 cholesterol
treatment guideline determines candidacy and treatment goal for lipid-lowering therapy
based on predicted 10-year Framingham risk for coronary heart disease. If one has 2 or more
non-cholesterol risk factors such as elevated blood pressure, even borderline LDL levels
may be sufficient to be classified as statin-eligible. Considering the day-to-day variability
and diagnostic inaccuracies of blood pressure measures, it is possible that a false positive
CBP reading results in both unnecessary anti-hypertensive and cholesterol-lowering
medications. Future research should evaluate the full spectrum of clinical and cost
implications of implementing secondary modalities in clinical practice, for both primary and
secondary prevention, and for a sufficiently long time frame. The identification of optimal
thresholds for secondary measurement modality and for treatment initiation, possibly for
different demographic subgroups, will have tremendous impact on driving the cost
efficiency of hypertension screening at the population level.
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Misclassification of Hypertension Status
*Typically defined as the average blood pressure during awake hours. ABPM is usually
viewed as the gold standard to reflect the average out-of-clinic blood pressure status.
†Masked hypertension carries higher risk for future cardiovascular events from untreated
hypertension[10]
‡ White coat hypertension results in unnecessary treatment costs and risk for adverse effects.
They constitute ~20% of newly diagnosed hypertensive patients [8] with 10% per year
progression rate to sustained hypertension [43]
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